SP
JSPR icon

Sequent Planning’s Jasper Therapeutics JSPR Stock Holding History

Sequent Planning’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.27K Hold
14,900
– – ﹤0.01% 269
2026
Q1 		$13.1K Buy
14,900
+2,400
+19% +$3.33K ﹤0.01% 242
2025
Q4 		$22.9K Hold
12,500
– – 0.01% 226
2025
Q3 		$29.8K Buy
12,500
+2,000
+19% +$6.07K 0.01% 201
2025
Q2 		$58.3K Buy
+10,500
New +$51.7K 0.02% 162

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sequent Planning's JSPR Position: Q2 2026 in Review

Sequent Planning held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 14,900 shares worth $6.27K. The position accounts for ﹤0.01% of the portfolio, ranked #269.

Sequent Planning first reported a position in JSPR in Q2 2025 and has held it in 5 quarters since. The position peaked at $58.3K in Q2 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Sequent Planning held 14,900 shares of Jasper Therapeutics worth $6.27K as of Q2 2026.
  • Sequent Planning left its Jasper Therapeutics share count unchanged in Q2 2026.
  • Jasper Therapeutics made up ﹤0.01% of Sequent Planning's portfolio in Q2 2026, its #269 holding.
  • Sequent Planning first reported a position in Jasper Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Sequent Planning's Jasper Therapeutics position peaked at $58.3K in Q2 2025.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Sequent Planning's 13F filing for Q2 2026, filed 14 Aug 2026.